Epidemiological Study of the Markers of Aging in the Cohort of Patient HIV in Brest
NCT ID: NCT06554210
Last Updated: 2024-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
213 participants
OBSERVATIONAL
2017-01-08
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
POPULATION CONCERNED: HIV-positive persons OBJECTIVE To describe the aging of the physiological functions of people living with HIV.
SECONDARY OBJECTIVES Assess the determinants (virus / HAART / Immunity / environment) Compare to the general population (historical comparisons) Compare to main body functions MAIN EVALUATION CRITERIA respiratory functional tests, memory test, IMTc, ECG, creatininemia, cancer, Fibroscan, bone densitometry...
SECONDARY EVALUATION CRITERIA Age, sex, phototype, CD4 lymphocytes count, viral load, nadir CD4, antiretroviral exposure, alcohol, tobacco ...
METHODOLOGY Monocentric retrospective study STATISTICS Frailty model, chi2 test, test U INCLUSION CRITERIA Seropositive for HIV, age\>18 years Follow-up at least once in the Internal Medicine department between 1995 and 2018 CRITERIA OF EXCLUSION Refusal of the patient or unreachable patient NUMBER OF PATIENTS Between 200 and 300 CALENDAR Duration of inclusions: 3 months Duration of participation of the patient: 20 years (retrospectives ...) Duration of the study: 1 year
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective, Observational Study to Examine the Effects of Ageing on the Clinical Outcomes of People Living With HIV in South Korea
NCT04914130
Evolution of the Clinical, Immuno-virological and Aging Trajectory of Patients Living With HIV
NCT06258122
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
NCT02663869
Accelerated Aging, HIV Infection, Antiretroviral Therapies
NCT01038999
Comorbidity and Aging With HIV
NCT01466582
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
HIV pathology has been associated with an accelerated aging of the infected organism, without anyone knowing how to do it:
* the direct toxicity of the virus;
* CD4 immuno-depletion and its corollary of opportunistic infections, modification of microbiota, ... ;
* Reactive immune stimulation with chronic inflammation;
* the toxicity of antiretrovirals, particularly nucleoside analogues, responsible for acquired mitochondrial cytopathy;
* And, finally, specific environmental factors related to either the mode of acquisition of the infection (transfusion, drug addiction ...), or the frailty induced by the pathology (psychic or social).
The discordant data of the great cohorts must be supported by cohorts of smaller sizes, more exhaustive, both in item and data, more homogeneous in their social determinants.
Population and Methods:
This retrospective monocentric epidemiological study has several objectives:
* Description of the aging of the population followed on several organs
* Comparison with the data of the closest general population geographically, sociologically and temporally;
* Comparison of the relative age of the different organs with each other: synchronous aging or not?
* Evaluation of a screening / surveillance strategy adapted to local epidemiology
1. Collect aging data from the functions:
Kidney: creatinine, calculated clearance of creatinine, microalbuminuria Liver: cytolysis, cholestasis, Fibroscan \* pulmonary: pulmonary function tests Heart: ultrasound, ECG Brain: memory disorder screening test Psychism: depression test Musculoskeletal: Bone Densitometry, Calcium, Phosphoremia, Vitamin D Vascular: carotid intima-media thickness
2. Evaluate the potential determinants:
Demographic: gender, age, phototype Viral: subtypes, time to infection, undetectable delay, viral load zenith Immune: lymphocyte immunophenotyping, nadir CD4 Iatrogen: antiretrovirals (year / patient exposure, compliance), other treatment Toxic: self-administered questionnaire (alcohol, tobacco and others), expired Hb CO, gammaGT, urinary toxicity test
3. Correlate aging data of each organ with determinants, correlate between organs with and without adjustment to determinants
4. Look for the closest population data in the literature and compared with those of the VIHVA cohort.
Ethical considerations:
The data of VIHVA study, approved by the local ethics committee (CCPPRB), was collected upon obtaining the non-opposition of patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* \<18 ans
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luc de Saint-Martin, MD, PhD
Role: STUDY_DIRECTOR
University Hospital, Brest
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Internal Medicine Department of University Hospital
Brest, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VIHVA 2016.CE31
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.